{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T08:54:59Z","timestamp":1791881699563,"version":"4.3.4"},"reference-count":43,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["HemaSphere"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    We report primary analysis results from the Phase 3 PERSPECTIVE study comparing ibrutinib + rituximab versus placebo + rituximab in patients with previously untreated follicular lymphoma requiring treatment per Groupe d'Etude des Lymphomes Folliculaires criteria who were ineligible for chemoimmunotherapy due to age and\/or comorbidities. The primary endpoint was investigator\u2010assessed progression\u2010free survival (PFS). Patients were randomly assigned 3:1 to receive ibrutinib (560\u2009mg) or placebo once daily until progression, together with rituximab 375\u2009mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    weekly for 4 weeks, then every 8 weeks for 12 cycles. Overall, 445 patients were assigned to receive ibrutinib + rituximab (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009334) or placebo + rituximab (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009111). With a median follow\u2010up of 53.7 months, PFS was significantly improved with ibrutinib + rituximab versus placebo + rituximab (hazard ratio, 0.713 [95% CI, 0.532\u20130.955]; P\u2009=\u20090.0231; median 42.0 vs. 32.8 months), as was overall response rate (81% vs. 68%; rate ratio, 1.190 [95% CI, 1.039\u20131.364]; P\u2009=\u20090.004). Complete response rates also favored ibrutinib + rituximab (31% vs. 26%). Overall survival (OS) was immature and not significantly different between arms (hazard ratio 1.121 [95% CI, 0.771\u20131.631]; P\u2009=\u20090.5485). Grade \u22653 adverse events occurred in 78% versus 57% of patients with ibrutinib + rituximab versus placebo + rituximab, most commonly neutropenia (16% vs. 7%), pneumonia (9% vs. 5%), hypertension (8% vs. 5%), COVID\u201019 (6% vs. 2%), COVID\u201019 pneumonia (6% vs. 3%), and diarrhea (6% vs. 2%). In patients with previously untreated follicular lymphoma, adding ibrutinib to rituximab significantly improved PFS and response rates but did not improve OS. This trial was registered at\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.clinicaltrials.gov\">www.clinicaltrials.gov<\/jats:ext-link>\n                    , NCT02947347.\n                  <\/jats:p>","DOI":"10.1002\/hem3.70400","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T14:57:14Z","timestamp":1781708234000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Phase 3 PERSPECTIVE study: Ibrutinib with rituximab for initial treatment of patients with follicular lymphoma"],"prefix":"10.1002","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4981-6188","authenticated-orcid":false,"given":"David","family":"Belada","sequence":"first","affiliation":[{"name":"4th Department of Internal Medicine \u2013 Haematology University Hospital and Faculty of Medicine Hradec Kr\u00e1lov\u00e9 Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faithlore P.","family":"Gardner","sequence":"additional","affiliation":[{"name":"Florida Cancer Specialists &amp; Research Institute Cape Coral Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana C.","family":"de Oliveira","sequence":"additional","affiliation":[{"name":"Catalan Institute of Oncology (ICO), Hospital Duran i Reynals, IDIBELL, Hospitalet Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan\u2010Manuel","family":"Sancho","sequence":"additional","affiliation":[{"name":"ICO\u2010Badalona Hospital Germans Trias i Pujol Badalona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elza","family":"Lomaia","sequence":"additional","affiliation":[{"name":"Almazov National Medical Research Centre St. Petersburg Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Wright","sequence":"additional","affiliation":[{"name":"Florida Cancer Specialists &amp; Research Institute Tampa Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Turgut","sequence":"additional","affiliation":[{"name":"Ondokuz May\u0131s University Samsun Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Martynova","sequence":"additional","affiliation":[{"name":"Department of Hematology and Chemotherapy Regional Clinical Hospital Krasnoyarsk Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsolt","family":"L\u00e1z\u00e1r","sequence":"additional","affiliation":[{"name":"Petz Alad\u00e1r University Teaching Hospital Gy\u0151r Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Anz","sequence":"additional","affiliation":[{"name":"Tennessee Oncology Chattanooga Tennessee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming\u2010Chung","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Hematology\u2010Oncology, Department of Internal Medicine Kaohsiung Chang Gung Memorial Hospital Kaohsiung Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Legiec","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplantation St. John of Dukla Oncology Center of Lublin Land Lublin Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Opat","sequence":"additional","affiliation":[{"name":"Department of Hematology Monash University Clayton Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junvie","family":"Pailden","sequence":"additional","affiliation":[{"name":"Department of Statistical Sciences AbbVie North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hillary M.","family":"Peltier","sequence":"additional","affiliation":[{"name":"Department of Clinical Development, Oncology AbbVie North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emerenziana","family":"Marturano","sequence":"additional","affiliation":[{"name":"Department of Clinical Development Oncology AbbVie Italy Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James P.","family":"Dean","sequence":"additional","affiliation":[{"name":"Department of Clinical Development, Oncology AbbVie North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian W.","family":"Flinn","sequence":"additional","affiliation":[{"name":"OneOncology\/Tennessee Oncology Nashville Tennessee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0132-x"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26737"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.07.014"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0016"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-3175"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.5376"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-531327"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805104"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2825"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.4786"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx768"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-02-003921"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2013.09.001"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-024-00551-1"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.8853"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-804641"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16424"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3163_80"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19787"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00775"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01073"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3411"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199311253292203"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-10-879643"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010298"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.08.674"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00843"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013526"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-62509-z"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35114"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00605"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.1652"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.7501"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000919"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04536-6"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01797"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2023.2256911"},{"key":"e_1_2_11_41_1","unstructured":"Centers for Disease Control and Prevention. Underlying conditions and the higher risk for severe COVID\u201019. February 6 2025.https:\/\/www.cdc.gov\/covid\/hcp\/clinical-care\/underlying-conditions.html"},{"key":"e_1_2_11_42_1","unstructured":"WangM MayerJ BeladaD et al. Acalabrutinib (A) plus bendamustine (B) and rituximab (R) in untreated mantle cell lymphoma: results from the phase 3 double\u2010blind placebo (P)\u2010controlled ECHO trial. Presented at: European Hematology Association 2024 Hybrid Congress; June 13\u201016 2024; Madrid Spain."},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2409804"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-02265"}],"container-title":["HemaSphere"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hem3.70400","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hem3.70400","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hem3.70400","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T08:34:23Z","timestamp":1791880463000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hem3.70400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1002\/hem3.70400"],"URL":"https:\/\/doi.org\/10.1002\/hem3.70400","archive":["Portico"],"relation":{},"ISSN":["2572-9241","2572-9241"],"issn-type":[{"value":"2572-9241","type":"print"},{"value":"2572-9241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"2025-09-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70400"}}